<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226134</url>
  </required_header>
  <id_info>
    <org_study_id>965-Med/ERC-08</org_study_id>
    <nct_id>NCT01226134</nct_id>
  </id_info>
  <brief_title>Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia</brief_title>
  <acronym>EIGEAPFD</acronym>
  <official_title>Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pathogenesis of functional dyspepsia is poorly understood. Gastrointestinal motor
      abnormalities, Helicobacter pylori infection, impaired gastric accommodation to a meal,
      hypersensitivity of the afferent nerves of the gut, psychological disturbances and central
      nervous system dysfunction have been proposed.

      Pharmacological treatments for patients with functional dyspepsia remain unsatisfactory. Only
      small benefits relative to placebo have been found with histamine H2 receptor antagonists,
      proton pump inhibitor and Helicobacter pylori eradication.

      Itopride is a dopamine antagonist with acetylcholinesterase inhibitory actions. This agent is
      currently indicated for patients with various upper GI symptoms.

      This study is aimed to evaluate the effect of Itopride on gastric emptying(by 13-C Octanoic
      acid breath Test), accommodation (by Gastric Scintigraphy SPECT and slow nutrient drinking
      test)and symptoms in FD patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      phase3 clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of Itopride on Gastric Emptying,accommodation and capacity of tolerating a nutrient drink in patients with Functional Dyspepsia</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of Itopride on symptom improvement in patient with Functional Dyspepsia</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Gastric Emptying</condition>
  <condition>Gastric Accommodation</condition>
  <arm_group>
    <arm_group_label>1.Itopride Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.Control placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive placebo tablets for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride,</intervention_name>
    <description>Itopride,50 mg capsules,thrice a day,for Four weeks</description>
    <arm_group_label>1.Itopride Group</arm_group_label>
    <other_name>Gananton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules,thrice a day for four weeks</description>
    <arm_group_label>2.Control placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All adult male or non-pregnant female patients who are diagnosed as functional
             dyspepsia and fulfilling Rome III criteria (1) will be considered

          2. Patients should be negative for H. pylori on gastric biopsy and Urea Breath Test.

          3. duodenal biopsy in these patients should be negative for giardiasis or celiac disease
             or any other established organic pathology

          4. A normal upper abdominal ultrasound

          5. Willing to participate and give consent for participation in the study.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Helicobacter Pylori positive on gastric biopsy and / or UBT.

          3. Taking other medications that alter gastric motility like macrolide

               -  anti-emetics and antibiotics .

          4. Pregnant or breast-feeding females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahab Abid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahab Abid, MD</last_name>
    <phone>+92 21 4864656</phone>
    <phone_ext>4656</phone_ext>
    <email>shahab.abid@aku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wasim Jafri, MD</last_name>
    <phone>+92 21 4864659</phone>
    <phone_ext>4659</phone_ext>
    <email>wasim.jafri@aku.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shahab Abid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wasim Jafri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maseeh Uzzaman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rakhshanda Bilal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soobia Siddiqui, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greger Lindberg, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>October 21, 2010</last_update_submitted>
  <last_update_submitted_qc>October 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Shahab Abid</name_title>
    <organization>Aga Khan University,Karachi, Pakistan</organization>
  </responsible_party>
  <keyword>Functional Dyspepsia</keyword>
  <keyword>Itopride</keyword>
  <keyword>Gastric Emptying</keyword>
  <keyword>Gastric Accommodation</keyword>
  <keyword>Dyspeptic Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

